[HTML][HTML] Cardiac transmembrane ion channels and action potentials: cellular physiology and arrhythmogenic behavior

V András, J Tomek, N Nagy, L Virág… - Physiological …, 2021 - journals.physiology.org
Cardiac arrhythmias are among the leading causes of mortality. They often arise from
alterations in the electrophysiological properties of cardiac cells and their underlying ionic …

[HTML][HTML] Computational modeling of cardiac electrophysiology and arrhythmogenesis: toward clinical translation

NA Trayanova, A Lyon, J Shade… - Physiological …, 2023 - pmc.ncbi.nlm.nih.gov
The complexity of cardiac electrophysiology, involving dynamic changes in numerous
components across multiple spatial (from ion channel to organ) and temporal (from …

Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block

J Tomek, A Bueno-Orovio, E Passini, X Zhou… - Elife, 2019 - elifesciences.org
Human-based modelling and simulations are becoming ubiquitous in biomedical science
due to their ability to augment experimental and clinical investigations. Cardiac …

Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative

Z Li, BJ Ridder, X Han, WW Wu, J Sheng… - Clinical …, 2019 - Wiley Online Library
The International Council on Harmonization (ICH) S7B and E14 regulatory guidelines are
sensitive but not specific for predicting which drugs are pro‐arrhythmic. In response, the …

Calibration of ionic and cellular cardiac electrophysiology models

DG Whittaker, M Clerx, CL Lei… - … Systems Biology and …, 2020 - Wiley Online Library
Cardiac electrophysiology models are among the most mature and well‐studied
mathematical models of biological systems. This maturity is bringing new challenges as …

Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14/S7B updates)

DG Strauss, WW Wu, Z Li, J Koerner… - Clinical Pharmacology …, 2021 - Wiley Online Library
After multiple drugs were removed from the market secondary to drug‐induced torsade de
pointes (TdP) risk, the International Council for Harmonisation (ICH) released guidelines in …

Mechanistic model‐informed proarrhythmic risk assessment of drugs: review of the “CiPA” initiative and design of a prospective clinical validation study

J Vicente, R Zusterzeel, L Johannesen… - Clinical …, 2018 - Wiley Online Library
The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative is developing and
validating a mechanistic‐based assessment of the proarrhythmic risk of drugs. CiPA …

Today's challenges to de-risk and predict drug safety in human “mind-the-gap”

RJ Weaver, JP Valentin - Toxicological Sciences, 2019 - academic.oup.com
Current gaps in drug safety sciences can result from the inability (1) to identify hazard across
multiple target organs,(2) to predict and risk assess with certainty against drug safety …

Comprehensive in vitro proarrhythmia assay (CiPA) update from a cardiac safety research consortium/health and environmental sciences institute/FDA meeting

DG Strauss, G Gintant, Z Li, W Wu… - Therapeutic …, 2019 - journals.sagepub.com
A Cardiac Safety Research Consortium/Health and Environmental Sciences Institute/FDA-
sponsored Think Tank Meeting was convened in Washington, DC, on May 21, 2018, to bring …

A computational pipeline to predict cardiotoxicity: from the atom to the rhythm

PC Yang, KR DeMarco, P Aghasafari, MT Jeng… - Circulation …, 2020 - Am Heart Assoc
Rationale: Drug-induced proarrhythmia is so tightly associated with prolongation of the QT
interval that QT prolongation is an accepted surrogate marker for arrhythmia. But QT interval …